Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells

Biomarkers

Volumn 14, Issue 4, 2009, Pages 258-270

  Konjević, Gordana ^a,b   Miräjaić Martinovi, Katarina ^a   Jurišić, Vladimir ^c   Babović, Nada ^a   Spužić, Ivan ^a,b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

CD158a; CD158b; Cytotoxicity; Melanoma; NK cells; NKG2D

Indexed keywords

BIOLOGICAL MARKER; CD16 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; BLOOD; IMMUNOLOGY; METASTASIS; MIDDLE AGED; SKIN TUMOR;

ADULT; AGED; ANTIGENS, CD3; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IGG; RECEPTORS, KIR2DL1; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 68549125484     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902814658     Document Type: Article

References (77)

1. Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, Bihl F, Braud VM. (2005). Cutting edge: lectinlike transcript 1 is a ligand for the CD161 receptor. J Immunol 175:7791-7795
2. Azzoni L, Anegon I, Calabretta B, Perussia B. (1995). Ligand binding to Fc gamma R induces c-myc-dependent apoptosis in IL-2- stimulated NK cells. J Immunol 154:491-499
3. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. (1998). Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 161:3493-3500
4. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann Rev Immunol 17:189-220.
5. Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Peña J, Solana R. (1999). NK phenotypic markers and IL-2 response in NK cells from elderly people. Exp Gerontol 34:253-265
6. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. (1985). The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 81:207-214
7. Caligiuri MA. (2008). Human natural killer cells. Blood 112:461-469
8. Campillo JA, Martínez-Escribano JA, Moya-Quiles MR, Marín LA, Muro M, Guerra N, Parrado A, Campos M, Frías JF, Minguela A, García-Alonso AM, Alvarez-López MR. (2006). Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients. Clin Cancer Res 12:4822-4831
9. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P. (2007). CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89-94.
10. Ciszak L, Kosmaczewska A, Werynska B, Szteblich A, Jankowska R, Frydecka I. (2009). Impaired zeta chain expression and IFNgamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep 21:173-184
11. Colonna M. (1997). Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Immunol Rev 155:127-133 (Pubitemid 27076064)
12. Colonna M. (2008). NK cells: New issues and challenges. Eur J Immunol 38:2927-2929
13. Cooper MA, Fehniger TA, Caligiuri MA. (2001a). The biology of human natural killer-cell subsets. Trends Immunol 22:633-640
14. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. (2001b). Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146-3151
15. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D. (2004). NK cells: innate immunity against hematological malignancies? Trends Immunol 25:328-333.
16. Coudert JD, Held W. (2006). The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 16:333-343.
17. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. (2003). A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 33:381-391.
18. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. (2007). Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109:4816-4824
19. Farag SS, Caligiuri MA. (2006). Human natural killer cell development and biology. Blood Rev 20:123-137.
20. Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW. (2008). Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180:4606-4614
21. Galiani MD, Gonzalez R, Solana R, Peña J. (2002). Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176-183
22. Groh V, Wu J, Yee C, Spies T. (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738
23. Gryzwacz B, Kataria N, Verneris MR. (2007). CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Letter to the editor. Leukemia 21:356-359
24. Hayakawa Y, Smyth MJ. (2006). NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 18:176-185.
25. Held W. (2008). Tolerance and reactivity of NK cells: two sides of the same coin? Eur J Immunol 38:2930-2933.
26. Jackson A, Warner N. (1986). Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J, editors. Manual of Clinical Laboratory Immunology, 3rd edn. Washington DC: American Society for Microbiology. p. 226-235
27. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE. (2001). CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 31:3121-3127
28. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. (2007). Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 24:312-317
29. Kiessling R, Klein E, Wigzell H. (1975). 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112-117
30. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, Fenaux P, Chouaib S, Caignard A. (2006). Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20:463-470
31. Kogure T, Fujinaga H, Niizawa A, Hai LX, Shimada Y, Ochiai H, Terasawa K. (1999). Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4. Mediators Inflamm 8:313-318
32. Kogure T, Mantani N, Sakai S, Shimada Y, Tamura J, Terasawa K. (2003). Natural killer cytolytic activity is associated with the expression of killer cell immunoglobulin-like receptors on peripheral lymphocytes in human. Mediators Inflamm 12:117-121
33. Konjević G, Jović V, Jurisić V, Radulović S, Jelić S, Spuzić I. (2003). IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis 20:647-655
34. Konjević G, Jurisić V, Banićevic B, Spuzić I. (1999). The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 104:144-151
35. Konjević G, Mirjacić Martinović, K Vuletić, A; Jović, V; Jurisić, V; Babović, N Spuzić I. (2007). Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 24:1-11.
36. Konjević G, Spuzić I. (1992). Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells. J Clin Lab Immunol 38:83-93.
37. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE. (1995). Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 139:169-182.
38. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. (1986). The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480-4486
39. Lanier LL. (1998). NK cell receptors. Annu Rev Immunol 16:359-393
40. Lanier LL. (2005). NK cell recognition. Annu Rev Immunol 23:225-274
41. Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F. (2005). NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 175:5790-5798
42. Lee JC, Lee KM, Kim DW, Heo DS. (2004). Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335-7340.
43. Lima M, Teixeira MA, Queiros ML, Leite M, Santos AH, Justica B, Orfao A. (2001). Immunophenotypic characterization of normal blood CD56+lo versus CD56+hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood Cells Mol Dis 27:731-743
44. Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G. (2007). NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res 13:7459-7468
45. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 96:5640-5644
46. Måsbäck A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. (2001). Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 11:435-445
47. Nagler A, Lanier LL, Cwirla S, Phillips JH. (1989). Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183-3191
48. Naumova E, Mihaylova A, Ivanova M, Mihailova S. (2007). Impact of KIR/HLA ligand combinations on immune responses in malignantmelanoma. Cancer Immunol Immunother 56:95-100.
49. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. (2005). Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54:172-178
50. Nausch N, Cerwenka A. (2008). NKG2D ligands in tumor immunity. Oncogene 27:5944-5958
51. Pan XH, Guo KY, Song JG, Li JQ, Pang RQ. (2003). [Modulation of the rate of CD158a+/b+ cells by Th1-and Th2-like cytokines]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19:56-58.
52. Parham P. (2005a). Immunogenetics of killer cell immunoglobulinlike receptors. Mol Immunol 42:459-462
53. Parham P. (2005b). MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201-214
54. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L. (2001). Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076-1086
55. Peterson ME, Long EO. (2008). Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk. Immunity 29:578-588
56. Pozo D, Vales-Gomez M, Mavaddat N, Williamson SC, Chisholm SE, Reyburn H. (2006). CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid phingomyelinase. J Immunol 176:2397-2406
57. Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. (2003). Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158neg ative phenotype. Rheumatology (Oxford) 42:870-878
58. Raulet DH, Vance RE. (2006). Self-tolerance of natural killer cells. Nat Rev Immunol 6:520-531
59. Raulet DH. (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781-790
60. Robertson MJ, Ritz J. (1990). Biology and relevance of human natural killer cells. Blood 76:2421-2438
61. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Münz C, Thiel A, Moretta L, Ferlazzo G. (2007). CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178:4947-4955
62. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. (2005). Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 175:7796-7799
63. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. (2007). In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS ONE 2:e518.
64. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC. (1996). A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 125:369-375
65. Seidel MG, Freissmuth M, Pehamberger H, Micksche M. (1998). Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch Pharmacol 358:382-389
66. Sibbitt WL Jr, Bankhurst AD, Jumonville AJ, Saiki JH, Saiers JH, Doberneck RC. (1984). Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 44:852-856
67. Slingluff CL Jr, Reintgen D. (1993). Malignant melanoma and the prognostic implications of pregnancy, oral contraceptives, and exogenous hormones. Semin Surg Oncol 9:228-231
68. Solana R, Casado JG, Delgado E, DelaRosa O, Marín J, Durán E, Pawelec G, Tarazona R. (2007). Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother 56:101-109
69. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. (2007). Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 65:126-138.
70. Tarazona R, Casado JG, Delarosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Trowsdale J, Parham P. 2004. Mini-review: defense strategies and immunity-related genes. Eur J Immunol 34:7-17.
71. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P. (1997). Human diversity in killer cell inhibitory receptor genes. Immunity 7:753-763
72. Vivier E, Nunès JA, Vély F. (2004). Natural killer cell signaling pathways. Science 306:1517-1519
73. Warren HS, Skipsey LJ. (1991). Phenotypic analysis of a resting subpopulation of human peripheral blood NK cells: the FcR gamma III (CD16) molecule and NK cell differentiation. Immunology 72:150-157
74. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH. (1999). An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732
75. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. (2006). Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203:633-645
76. Zhang C, Zhang J, Wei H, Tian Z. (2005). Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity? Int Immunopharmacol 5:1099-1111
77. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE. (2007). Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18:159-170